BioVersys
@Bioversys
Followers
424
Following
59
Media
27
Statuses
177
BioVersys AG is a privately owned Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets.
Basel
Joined August 2013
📡 @Bioversys and @SHIONOGI_JP, enter into Global Research Collaboration for broad-spectrum NTM clinical candidates. Read more here: https://t.co/BtNb9pTwPi
0
3
4
Click https://t.co/kFuD18KsiL for an informative KOL event; May 7, 2025, 8:30 AM ET / 2:30PM CEST. Featuring Professor David Paterson & Dr. Andrew Shorr, MD, discussing the unmet need & current treatment landscape for carbapenem resistant Acinetobacter baumannii pneumonia. #AMR
0
3
4
BioVersys announces joining the @AMRAccelerator EU-funded programme @RespiriNTM, access to up to €2 m in non-dilutive funding for our broad-spectrum NTM project. Read the full press release here: https://t.co/zFUoKAuQtY
#SavingLivesinResistantTimes #AMR #investment #Innovation
0
5
6
📡 Exciting times as BioVersys announces last patient, last visit in the Phase 2 clinical trial with BV100 showing positive first signs of efficacy for #VABP #CRAB. 🎯🌍 🏥 🚀 Read the full press release here: https://t.co/SCom3zT3fm
#SavingLivesinResistantTimes #AMR #Innovation
0
4
6
BioVersys announces strategic investment from GIBF2 and launch of BV100 clinical program in China. · GIBF2 to invest US$ 6m in BioVersys · BV100 Phase 1 study in China expected to start in 1H 2025 Press release: https://t.co/dubXVfOl6m
#AMR #investment #China #Innovation
0
4
4
🤝 We are excited to collaborate with @lifearc1, @MedDiscCat and @cftrust to expedite BioVersys’ NTM program to address serious infections in people living with CF. 💊 See PR with details:
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
0
1
🎉 We're excited to announce that @Bioversys has been awarded with non-dilutive funding via our CDP programme to advance the pipeline of preclinical assets for CF lung infections. Read the press release https://t.co/VGmRFqlXwj
@MedDiscCat | @cftrust | @lifearc1
2
1
10
CHF 12.3 million to boost novel drugs against tuberculosis: TOP 100 Swiss scale-up @Bioversys secures its Series C and expands collaboration with GSK. Congrats to the world-class team led by biotech pioneers Marc Gitzinger, Sergio Lociuro, and Glenn Dale! https://t.co/PYVFbjt7Zz
0
2
8
BioVersys announces expansion of collaboration with GSK and extension of Series C (CHF 12.3m) to CHF 44.9m. BioVersys strives to bring urgently needed medicines to patients, with strong partners, @GSK, & loyal investors, we're firmly on track.🌍💊 Full PR:
0
4
7
🌐 Our new patient section is live, spotlighting our battle against AMR and our patient-centric solutions. Dive into innovation and join our mission to safeguard the future of the world’s healthcare. ➡️Check it out here: https://t.co/pymzd7PGWU.
#PatientCare #BioVersys
0
0
2
🚀 BioVersys & GSK achieve exciting milestone in TB treatment with the completion of the IMI2-funded TRIC-TB program & the introduction of alpibectir, a Phase 2-ready candidate. A giant leap towards overcoming TB! 🌍💊 #BioVersys #HealthcareInnovation
bioversys.com
Basel, Switzerland. March 5, 2024, 9am CET BioVersys and GSK successfully complete IMI2 programme reaching clinical milestone BioVersys AG, a multi-asset, clinical stage biopharmaceutical company...
0
2
11
Meet Jonathan Butcher at the European Life Sciences CEO Forum, Feb 28th-29th, 2024, Hilton Zurich, to dive into innovative AMR solutions! 🚀 Explore investment/collab opportunities with us. Book your slot via one-to-one or ir@bioversys.com. #AMRInnovation #LifeSciences #BioVersys
0
0
0
🚨 Exciting collaboration alert! #BioVersys & #HelmholtzCentre join forces against AMR! 🔬 🤝 Combining our R&D expertise to innovate and deliver new AMR solutions.💡 Supported by DZIF, we're tackling life-threatening infections together! Full PR 🔗:
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
1
4
🎉 Big news! @BioVersys has received FDA orphan-drug designation for our anti-TB drug candidate alpibectir, & ethionamide combo. A game-changer in fighting drug-resistant TB. 🌍 Read more: https://t.co/q78g9PpKqQ
bioversys.com
Basel, Switzerland. December 12, 2023, 9am CET BioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis BioVersys AG, a...
0
3
8
🌍 Join BioVersys in the fight against Antimicrobial Resistance! 🤝 Raise awareness during World AMR Awareness Week (18-24 Nov). 🎗️ Share to amplify the message and contribute to the global health cause. 💙 #AMRAwareness #OneHealth #SpreadTheWord #StopAMR #BioVersys
0
2
7
🌟Major Step for BioVersys! Thrilled to introduce Hernan Levett as our new CFO. His 30-year track record will fortify our financial strategy as we approach vital milestones.👉See attached press release for details. https://t.co/Mo3JNzYzca 🔗#BioVersysTalks #NewCFO
bioversys.com
Basel, Switzerland. November 01, 2023, 9am CET Hernan Levett joins BioVersys AG as new CFO to support the next stage of corporate development BioVersys AG, a multi-asset, clinical stage biopharmace...
0
0
2
BioVersys is excited to be part of #BIOEurope in Munich, taking place from November 6 to 8, 2023. We invite you to request a partnering meeting with us at the event. Let's connect and explore opportunities together! Learn more: https://t.co/ryRxCzuNko
informaconnect.com
Join 5,800+ life science professionals at BIO-Europe 2025 in Vienna, November 3-5. Connect with global biopharma leaders and drive strategic partnerships forward.
0
0
1
Our CEO will represent BEAM Alliance at the World Health Summit in Berlin today. Join experts to discuss sustainable new antibiotics. Hosted by https://t.co/daHjHD3BJX. 📅 Oct. 16, 2023, 🕓CEST: 04:00 PM 🖥️ Join here: https://t.co/RgOBImy5iT Stay tuned! #BEAMAlliance #Antibiotics
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
0
4
Meet Dr. Nawaz Khan, the new Head of Research at BioVersys! Specializing in antimicrobial drug development, he’s set to boost our R&D and collaborations. Welcome aboard, Nawaz! 🚀 #newhire #BioVersys
0
0
5